Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 177   

Articles published

BMY 67.89 -0.19 (-0.28%)
price chart
Large Outflow of Money Witnessed in Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE:BMY) managed to eke out gains of 0.25% in intraday trade. The share price increased by 0.17 points to $67.99.
Bristol Myers Squibb Co (BMY) Files Form 4 Insider Selling : Lamberto ...  Insider Trading Report
Bristol-Myers Squibb Company (NYSE:BMY) - Large Cap Morning Report  Wall Street Observer
Earnings Preview: Merck & Co., Inc., Pfizer Inc., and Bristol-Myers Squibb Co
In particular, a number of large-cap drugmakers will take to the confessional, including Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and Bristol-Myers Squibb Co (NYSE:BMY). Below, we'll take the pre-earnings temperature of MRK, PFE, and BMY.
Bristol-Myers Squibb Co (BMY) Earnings Report: Q3 2015 Conference Call ...
Bristol-Myers Squibb's Opdivo (nivolumab) Recipient of Prix Galien USA ...  Business Wire (press release)
Bristol-Myers Squibb Co (BMY) Had Its Target Price Increases by Professional ...
In analysts report shared with investors and clients by Jefferies & Co on Wednesday, 18 November, Bristol-Myers Squibb Co (BMY) had its target upped to $70.00. The firm at present has “Hold” rating on the stock. The target increase is well-received by ...
Price Target Update on Bristol-Myers Squibb Company (NYSE:BMY)  Money Flow Index
Shares of Bristol-Myers Squibb Company (NYSE:BMY) Sees Large Outflow of Money  News Watch International
Bristol-Myers Squibb Company (NYSE:BMY): A Look at Earnings
Sell-side brokerage firm are predicting that Bristol-Myers Squibb Company (NYSE:BMY) will post earnings per share of $0.63 for the current fiscal quarter.
UBS Upgrades Bristol-Myers Squibb Co. (BMY) to Buy; More Bullish on Opdivo
UBS upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Neutral to Buy with a price target of $75.00 (from $65.00), saying they like the opportunity "right here, right now.
Bristol Myers Squibb Company (NYSE:BMY): 11 Analysts Expecting Sales of 3845.775
Today's market news: Bristol Myers Squibb Company trades against a 52 week low of 51.82 and a 52 week of high 70.54. Technical indicators show a 50 day moving average of 65.26.
Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in ...  Business Wire (press release)
Bristol-Myers Squibb Company Short Interest Update  News Watch International
Bristol-Myers Squibb's Kidney Opportunity Is Bigger Than Some Thought
A couple of months ago, Bristol-Myers released positive top-line kidney cancer data, but investors did not seem to care much, focusing instead on lung cancer.
Bristol-Myers Squibb Selects ZS to Support Global Commercial Analytics  PR Newswire (press release)
Why You Should Buy At New Highs: Vonage Holdings Corp (NYSE:VG), Exelixis ...  Wall Street Point
Bristol-Myers Squibb Co (BMY) Takeover Speculation. Wall Street Buys Calls
Bristol-Myers Squibb Co (NYSE:BMY) October 62.5 and 67.5 calls are active on total call volume of 39K compare to 11K puts on the subject of takeover speculation.
Storm The Castle: Bristol-Myers Squibb Company (BMY)
Bristol-Myers Bullish Option Trades Rise on Deal Speculation  Bloomberg
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's "Barbarian At The ...
Trade-Ideas LLC identified Bristol-Myers Squibb Company ( BMY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate.
Analyst Price Target Update on Bristol-Myers Squibb Company  American Trade Journal
Bristol-Myers deal for Cardioxyl could make Triangle life sciences history  Triangle Business Journal
Bristol-Myers Squibb buying Cardioxyl, developer of heart failure drug, for up ...
TRENTON, N.J. - Bristol-Myers Squibb Co. is acquiring a private biotech company developing a medicine for one of the most common cause of hospitalizations in senior citizens, in a deal that could be worth up to $2.1 billion.
One Reason Bristol-Myers Squibb (BMY) Stock is Declining Today